October 2018
Volume 4, Issue 12
This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.
Table of Contents
October 2018 Issue
Recommendations from My Bookshelf: A Bloody Mess
Imagine that you’re young, brilliant, charismatic, and you have a compelling vision for a bold new idea that could revolutionize health care: scores of...
October 2018 Issue
Announcing the 2018 Honorific and Mentor Award Recipients, and more
Announcing the 2018 Honorific and Mentor Award Recipients!
ASH will recognize these distinguished leaders in hematology through awards and special lectures at the 60th ASH...
Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...
Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors
NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...
October 2018 Issue
The Realities of “Right to Try”
In May 2018, President Donald Trump signed into law the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of...
Let’s Get Cooking: Jonathan Hoggatt, PhD
In this edition, Jonathan G. Hoggatt, PhD, discusses his passion for the delicious art of cooking.
Hear more from our interview with Dr. Hoggatt in...
Pulling Back the Curtain: Vip Viprakasit, MD, DPhil
In this edition, Vip Viprakasit, MD, DPhil, talks about working in a limited-resource setting, falling in love with the red cell, and his surprising...
October 2018 Issue
Demystifying Epigenetics in Hematology
In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...
How would you treat a patient with autoimmune hepatitis, grade 4 cirrhosis, and declining...
Here’s how readers responded to a You Make the Call question about a 22-year-old patient presenting with epistaxis, a platelet count of zero, abnormal...
How would you treat a patient with autoimmune hepatitis, grade 4 cirrhosis, and declining...
This month, Spero Cataland, MD, discusses whether a patient with thrombocytopenia has hypersplenism, immune thrombocytopenia, or both.
And don't forget to check out next month's...
October 2018 Issue
Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia
Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...
Phase I Trial Shows Activity of Single-Agent Ivosidenib in IDH1-Mutated AML
Ivosidenib was safe and associated with remissions, transfusion independence, and molecular remissions in patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML), according...
Oral L-Glutamine Powder Lowers Frequency of Sickle Cell–Related Pain Episodes
Oral L-glutamine powder, with or without hydroxyurea, reduced the number of pain events experienced by children and adults with sickle cell disease (SCD), compared...
FDA Warns Against Using Azithromycin After Stem Cell Transplant
The U.S. Food and Drug Administration (FDA) issued a statement advising clinicians to avoid using the antibiotic azithromycin in patients with certain cancers who...
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...
FDA Approves Mogamulizumab-kpkc for Two Types of Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc for intravenous use in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome...
Can a Liquid Biopsy Predict Outcomes in DLBCL?
In a study of patients with diffuse large B-cell lymphoma (DLBCL), levels of pretreatment circulating tumor DNA (ctDNA) and molecular responses were independent predictors...
New Immunotherapy Approach Shows Activity in NCI Trials
Treatment with tumor-infiltrating lymphocytes (TILs), a new type of immunotherapy, induced complete remission in a patient with breast cancer, according to a report by...
Lusutrombopag Approved for Thrombocytopenia in Chronic Liver Disease
The U.S. Food and Drug Administration has approved lusutrombopag for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to...
FDA Approves Second Filgrastim Biosimilar
Filgrastim-aafil received approval from the U.S. Food and Drug Administration (FDA), making it the second approved biosimilar version of filgrastim. The treatment was given...
October 2018 Issue
From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
